Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LDHA | P00338 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9263666 | 0.86 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL9264609 | 0.86 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL1129788 | 0.85 | LMNA (0.63) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL10808024 | 0.85 | LMNA (0.55) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL20446813 | 0.81 | LMNA (0.55) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL93033 | 0.80 | GAA (0.40) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL93031 | 0.79 | LMNA (0.42) | LMNAGAAKMT2ALDHA | |
| SCHEMBL10271760 | 0.79 | LMNA (0.40) | LMNAGAAKMT2AALDH1A1LDHA | |
| SCHEMBL19346642 | 0.78 | LDHA (0.39) | LMNAGAAKMT2ALDHAMAPT | |
| SCHEMBL13946439 | 0.78 | KMT2A (0.38) | LMNAGAAKMT2ALDHAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | disclosed |
| US-9802959-B2 | Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones | SHIONOGI & CO., LTD. (JP) | 2017-10-31 | — | — | US | disclosed |
| EP-2370419-B1 | MALTOL ETHER PROCESSES AND INTERMEDIATES | SHIONOGI & CO (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170267693-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20170260203-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| EP-2376080-B1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-20170253616-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3210603-A1 | SYNTHESIS OF CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS AND INTERMEDIATES | SHIONOGI & CO., LTD (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170240564-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| WO-2010011814-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| WO-2009021948-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | GE HEALTHCARE AS (NO) | 2009-02-19 | — | — | WO | disclosed |
| US-20080200520-A1 | Iron Modulators | BTG INTERNATIONAL LIMITED | 2008-08-21 | — | — | US | disclosed |
| EP-1950212-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | Shionogi Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080096974-A2 | Polyamine-Metal Chelator Conjugates | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007002109-A2 | MULTIDENTATE PYRONE-DERIVED CHELATORS FOR MEDICINAL IMAGING AND CHELATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | LMNA 4549/4885GAA 3617/4885KMT2A 574/4885 |
| US-20080200520-A1 | Iron Modulators | SLC40A1, HAMP, FTH1 | LMNA 1798/4885GAA 1151/4885KMT2A 3533/4885 |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | LMNA 2182/4885GAA 505/4885KMT2A 1146/4885 |
| US-20170260203-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | LMNA 4751/4885GAA 3623/4885KMT2A 390/4885 |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | CDK20, CYP4A22, CDK10 | LMNA 969/4885GAA 4656/4885KMT2A 214/4885 |
| US-20170240564-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | LMNA 2283/4885GAA 2510/4885KMT2A 1061/4885 |
| US-20080096974-A2 | Polyamine-Metal Chelator Conjugates | SLC7A1, SLC40A1, SRM | LMNA 1556/4885GAA 1460/4885KMT2A 1031/4885 |
| US-20170253616-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | LMNA 4737/4885GAA 3695/4885KMT2A 375/4885 |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NCOA4, NR4A1, NR4A2 | LMNA 4744/4885GAA 3600/4885KMT2A 395/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | LMNA 4751/4885GAA 3615/4885KMT2A 378/4885 |
| US-20170267693-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | LMNA 4751/4885GAA 3623/4885KMT2A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.